PTI

Proteostasis
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.470
-0.130
-8.13%
After Hours: 1.530 +0.06 +4.08% 19:42 05/27 EDT
OPEN
1.600
PREV CLOSE
1.600
HIGH
1.610
LOW
1.470
VOLUME
2.13M
TURNOVER
--
52 WEEK HIGH
4.720
52 WEEK LOW
0.6100
MARKET CAP
76.66M
P/E (TTM)
-1.3827
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PTI stock price target is 5.50 with a high estimate of 8.00 and a low estimate of 3.000.

EPS

PTI News

More
Is Vertex Pharmaceuticals Stock a Buy?
MotleyFool.com · 3d ago
Proteostasis Therapeutics: A Clinical Stage Company That's Worth The Risk
Seeking Alpha - Article · 4d ago
Proteostasis Therapeutics EPS beats by $0.07
Proteostasis Therapeutics (NASDAQ:PTI): Q1 GAAP EPS of -$0.19 beats by $0.07. Cash, cash equivalents and short-term investments of $57.1M. Press Release 
seekingalpha · 05/16 01:13
Proteostasis Therapeutics (PTI) Reports Q1 Loss, Lags Revenue Estimates
Proteostasis (PTI) delivered earnings and revenue surprises of 17.39% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/15 21:25
Proteostasis Therapeutics Q1 EPS $(0.190) Up From $(0.280) YoY
Proteostasis Therapeutics (NASDAQ:PTI) reported quarterly losses of $(0.190) per share. This is a 32.14 percent increase over losses of $(0.280) per share from the same period last year.
Benzinga · 05/15 20:10
Proteostasis Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
Proteostasis Therapeutics, Inc. (Nasdaq: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced financial results for the first quarter ended March
PR Newswire · 05/15 20:10
Proteostasis Therapeutics to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF), today announced that Proteostasis management will present at the 2020
PR Newswire · 05/13 11:43
5 Top Stocks With Rising P/E to Bet On
Zacks · 05/12 14:02

Industry

Biotechnology & Medical Research
+0.53%
Pharmaceuticals & Medical Research
+0.23%

Hot Stocks

Symbol
Price
%Change

About PTI

Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of novel therapeutics to treat cystic fibrosis (CF), and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. The Company’s CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. The Company’s clinical developments include PTI-801, a third generation CFTR corrector, PTI-808, a CFTR potentiator, and PTI-428, a CFTR amplifier.
More

Webull offers kinds of Proteostasis Therapeutics Inc stock information, including NASDAQ:PTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTI stock news, and many more online research tools to help you make informed decisions.